Immunome Inc. Presenting Human Monoclonal Antibody Platform at Pharmaceutical Consulting Consortium, Inc. (PCCI)
Wynnewood, PA, November 08, 2009 --(PR.com)-- Immunome, Inc., President and CEO, Tim Pelura, Ph.D., will be presenting information about the company on Monday, November 9, 2009 at the Pharmaceutical Consulting Consortium, Inc. (PCCI) Meeting. The presentation will be also be available for viewing via webcast at www.rxpcci.com.
Immunome is a start-up biopharmaceutical company located in the biotechnology incubator at the Lankenau Institute for Medical Research in Wynnewood, PA. Immunome has a proprietary technology for cloning “native” human antibodies (N-huMAbs), high-affinity IgG antibodies that maintain the exact, protective configurations created by the healthy human immune system. Immunome’s N-huMAbs are ideal for use as therapeutics and diagnostics in many areas including infectious disease, neurology, biodefense, and cancer. Immunome’s technology platform includes IP from Thomas Jefferson University and the Whitehead Institute for Biomedical Research. Immunome has been funded by an SBIR grant from the National Institute for Allergy and Infectious Disease and recently raised $435,000 in angel funding to support expansion of their discovery program. Immunome is actively seeking academic and industrial partners interested in developing and commercializing human monoclonal antibodies.
At Immunome, Inc., Tim Pelura, Ph.D. serves as the President and CEO. Dr. Pelura is a serial life science entrepreneur with over 35 years of experience in the pharmaceutical, biotech and medical device industries and has been pivotal in the development of several new drugs spanning numerous therapeutic areas. Prior to joining Immunome, Dr. Pelura was founding CEO of Promedior, a Pennsylvania biotech company developing novel therapeutics for the treatment of fibrotic disorders and diseases. He has held various executive positions at several biotech and pharmaceutical companies, including Kereos, Provasis Therapeutics, Neuron Therapeutics, Alliance Pharmaceuticals, and Pharmacia. Dr. Pelura’s executive team at Immunome includes Scott Dessain, M.D., Ph.D., Founder and Chief Scientific Officer, and George Hobbs, J.D., SVP of Corporate Development.
About Pharmaceutical Consulting Consortium, Inc. (PCCI)
The Pharmaceutical Consulting Consortium, Inc., is a social/networking group of former pharmaceutical executives, managers and talent. Many offer their services as consultants to the healthcare industry. They hold meetings monthly beginning around 6:30 pm with refreshments and chat, followed by dinner with a presentation by a guest speaker and discussion.
###
Immunome is a start-up biopharmaceutical company located in the biotechnology incubator at the Lankenau Institute for Medical Research in Wynnewood, PA. Immunome has a proprietary technology for cloning “native” human antibodies (N-huMAbs), high-affinity IgG antibodies that maintain the exact, protective configurations created by the healthy human immune system. Immunome’s N-huMAbs are ideal for use as therapeutics and diagnostics in many areas including infectious disease, neurology, biodefense, and cancer. Immunome’s technology platform includes IP from Thomas Jefferson University and the Whitehead Institute for Biomedical Research. Immunome has been funded by an SBIR grant from the National Institute for Allergy and Infectious Disease and recently raised $435,000 in angel funding to support expansion of their discovery program. Immunome is actively seeking academic and industrial partners interested in developing and commercializing human monoclonal antibodies.
At Immunome, Inc., Tim Pelura, Ph.D. serves as the President and CEO. Dr. Pelura is a serial life science entrepreneur with over 35 years of experience in the pharmaceutical, biotech and medical device industries and has been pivotal in the development of several new drugs spanning numerous therapeutic areas. Prior to joining Immunome, Dr. Pelura was founding CEO of Promedior, a Pennsylvania biotech company developing novel therapeutics for the treatment of fibrotic disorders and diseases. He has held various executive positions at several biotech and pharmaceutical companies, including Kereos, Provasis Therapeutics, Neuron Therapeutics, Alliance Pharmaceuticals, and Pharmacia. Dr. Pelura’s executive team at Immunome includes Scott Dessain, M.D., Ph.D., Founder and Chief Scientific Officer, and George Hobbs, J.D., SVP of Corporate Development.
About Pharmaceutical Consulting Consortium, Inc. (PCCI)
The Pharmaceutical Consulting Consortium, Inc., is a social/networking group of former pharmaceutical executives, managers and talent. Many offer their services as consultants to the healthcare industry. They hold meetings monthly beginning around 6:30 pm with refreshments and chat, followed by dinner with a presentation by a guest speaker and discussion.
###
Contact
Lankenau Institute for Medical Research
Tava Shanchuk
484-476-3429
www.limr.org
Tim Pelura
610-745-4735
tjpelura@gmail.com
Contact
Tava Shanchuk
484-476-3429
www.limr.org
Tim Pelura
610-745-4735
tjpelura@gmail.com
Categories